Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1856 Target Snapshot

3-oxo-5-alpha-steroid 4-dehydrogenase 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
757Compounds
118Assays
2Approved Drugs
693.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

3-oxo-5-alpha-steroid 4-dehydrogenase 2 shows approved-linked disease relevance led by alopecia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P31213. Start with alopecia, then reuse UniProt P31213 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with alopecia, then reuse UniProt P31213 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
alopecia

3-oxo-5-alpha-steroid 4-dehydrogenase 2 shows approved-linked disease relevance led by alopecia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with alopecia because it currently carries approved-linked support. Linked drugs include FINASTERIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3-oxo-5-alpha-steroid 4-dehydrogenase 2 as ChEMBL target CHEMBL1856, mapped to UniProt P31213. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3-oxo-5-alpha-steroid 4-dehydrogenase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1856
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P31213
3-oxo-5-alpha-steroid 4-dehydrogenase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3-oxo-5-alpha-steroid 4-dehydrogenase 2 is the right protein anchor across sources, using UniProt P31213 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why alopecia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name3-oxo-5-alpha-steroid 4-dehydrogenase 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP31213
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3-oxo-5-alpha-steroid 4-dehydrogenase 2
UniProt AccessionP31213
Component TypeProtein
Sequence Length254 aa

3-oxo-5-alpha-steroid 4-dehydrogenase 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 3-oxo-5-alpha-steroid 4-dehydrogenase 2, mapped to UniProt P31213. Sequence length is 254 aa.

Mapped IDP31213
Review name3-oxo-5-alpha-steroid 4-dehydrogenase 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

3-oxo-5-alpha-steroid 4-dehydrogenase 2 shows approved-linked disease relevance led by alopecia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
alopecia
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Approved-linked Approved
androgenetic alopecia
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Approved-linked Approved
benign prostatic hyperplasia
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Approved-linked Approved
hypotrichosis
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Approved-linked Approved
prostate adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Approved-linked Approved
prostate carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugFINASTERIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with alopecia because it currently carries approved-linked support. Linked drugs include FINASTERIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasealopecia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC50591.0
KI102.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL138173 10.4 IC50 0.04 Preclinical
CHEMBL2282783 10.4 IC50 0.04 Preclinical
CHEMBL137733 10.15 IC50 0.07 Preclinical
CHEMBL2282782 10.15 IC50 0.07 Preclinical
CHEMBL2282766 10.1 IC50 0.08 Preclinical
CHEMBL420020 10.1 IC50 0.08 Preclinical
CHEMBL420020 10.1 Ki 0.08 Preclinical
CHEMBL2282775 10.05 IC50 0.09 Preclinical
CHEMBL2282776 10.05 IC50 0.09 Preclinical
CHEMBL24088 10.05 IC50 0.09 Preclinical
Distribution

pChEMBL Value Distribution

21
5.0
34
5.5
59
6.0
57
6.5
54
7.0
45
7.5
81
8.0
55
8.5
31
9.0
44
9.5
pChEMBL
Approved Drugs

Approved Drugs

FINASTERIDE
CHEMBL710
Approved 1992
Properties Compare Identifier
Assay Landscape

Assay Landscape

118
Total Assays
421
Tested Compounds
2
Assay Types
Binding — 114 assays, 421 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 61 288 7.9
cell-based format 23 81 7.0
tissue-based format 23 35 7.2
assay format 7 17 7.1
Functional — 4 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 3 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine